Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma.

Müller, Nadja

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma. [electronic resource] - Journal of immunotherapy (Hagerstown, Md. : 1997) Jun 2015 - 197-210 p. digital

Publication Type: Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't

1537-4513

10.1097/CJI.0000000000000082 doi


Animals
Cell Line
Cell- and Tissue-Based Therapy
Chemokine CXCL12--biosynthesis
Chemotaxis--genetics
Cytotoxicity, Immunologic
Disease Models, Animal
Ectopic Gene Expression
ErbB Receptors--immunology
Female
Gene Expression
Gene Order
Genetic Therapy
Genetic Vectors--administration & dosage
Glioblastoma--etiology
Humans
Immunotherapy
Killer Cells, Natural--immunology
Lentivirus--genetics
Mice
Receptors, Antigen, T-Cell--genetics
Receptors, CXCR4--genetics
Recombinant Fusion Proteins--genetics
Transduction, Genetic
Tumor Burden
Xenograft Model Antitumor Assays